



EMA/560202/2020

AZILECT

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
WS/1749	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Submission of the final report from study TV1030-CNS-50024 listed as a category 3 study in the RMP.</p>	03/09/2020		SmPC and PL	The SmPC section 4.4 was updated to include the results of a retrospective cohort study which suggested a possibly increased risk of melanoma with the use of rasagiline, especially in patients with longer duration of rasagiline exposure and/or with the higher (1mg) dose of rasagiline. Any suspicious skin lesion should be evaluated by a

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>This is a non-interventional retrospective cohort study which was conducted using the United States Medicare research database to assess the potential risk of melanoma associated with the use of rasagiline mesylate in patients with Parkinson's disease.</p> <p>Section 4.4. of SmpC was updated to amend the information on the risk of melanoma associated with the use of rasagiline. The package leaflet is updated in accordance.</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>				<p>specialist. Patients should therefore be advised to seek immediate medical review if a new or changing skin lesion is identified.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>
WS/1789/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p>	17/04/2020	n/a		
WS/1771/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p>	12/03/2020	n/a		

	<p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p>				
PSUSA/2612/201901	Periodic Safety Update EU Single assessment - rasagiline	05/09/2019	n/a		PRAC Recommendation - maintenance
IAIN/0083	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	26/07/2019	n/a		
IA/0081	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	07/03/2019	n/a		
IA/0080/G	<p>This was an application for a group of variations.</p> <p>B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)</p> <p>B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)</p>	21/06/2018	06/06/2019	SmPC, Labelling and PL	

	B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)				
WS/1361	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product</p>	21/06/2018	06/06/2019	SmPC, Labelling and PL	
N/0078	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/01/2018	06/06/2019	PL	
WS/1168	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4, 4.7 and 4.8 to include a new warning on excessive daytime sleepiness and sudden sleep onset episodes, update of section 4.9 to remove 'dysphoria' as a symptom reported following overdose of rasagiline based on a CCDS update. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the Worksharing applicant (WSA) took the opportunity to make editorial changes throughout the PI, to correct the invented name for Rasagiline Ratiopharm in the Czech annexes and to bring the PI in line with the latest QRD template version 10.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to</p>	01/09/2017	20/12/2017	SmPC, Annex II, Labelling and PL	Based on new available Pharmacovigilance data, a signal of sudden onset of sleep/sleep attack was raised. Excessive daily sleepiness (hypersomnia, lethargy, sedation, sleep attacks, somnolence, sudden onset of sleep) can occur in patients treated with dopamine agonists and/or other dopaminergic treatments. A similar pattern of excessive daily sleepiness has been reported post-marketing with rasagiline. Although many of these patients reported somnolence while on rasagiline with other dopaminergic medicinal products, some perceived that they had no warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events have been reported more than 1-year after initiation of treatment. In patients experiencing somnolence/sudden sleep episodes, rasagiline may have major influence on the ability to drive and use machines. Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are

	new quality, preclinical, clinical or pharmacovigilance data				reasonably certain that rasagiline does not affect them adversely. Patients being treated with rasagiline and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until they have gained sufficient experience with rasagiline and other dopaminergic medications to gauge whether or not it affects their mental and/or motor performance adversely. In addition as the term 'dysphoria' can be attributed to cognitive effects of serotonin syndrome, it was removed from the list of symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg.
IG/0789/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p>	18/04/2017	n/a		

	B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method				
WS/0984	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	09/02/2017	n/a		
IAIN/0075/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	16/12/2016	20/12/2017	SmPC, Labelling and PL	
WS/0985/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No	27/10/2016	n/a		

	<p>1234/2008.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
PSUSA/2612/201601	Periodic Safety Update EU Single assessment - rasagiline	02/09/2016	n/a		PRAC Recommendation - maintenance
T/0071	<p>Marketing Authorization transfer from Teva Pharma GmbH to Teva B.V.</p> <p>Transfer of Marketing Authorisation</p>	28/01/2016	22/02/2016	SmPC, Labelling and PL	
IG/0648/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS</p> <p>B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS</p>	15/01/2016	n/a		

IAIN/0069/G	<p>This was an application for a group of variations.</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	21/12/2015	22/02/2016	Annex II and PL	
WS/0767/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP -</p>	06/08/2015	22/02/2016	Annex II and PL	

	Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process				
IB/0066	B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation	27/03/2015	n/a		
IA/0065	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	29/07/2014	n/a		
IB/0062	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	11/06/2014	n/a		
IA/0064	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	05/06/2014	n/a		
IAIN/0063/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or	28/05/2014	n/a		

	<p>manufacturer of a novel excipient</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p>				
IB/0061/G	<p>This was an application for a group of variations.</p> <p>B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p>	18/03/2014	n/a		
PSUV/0060	Periodic Safety Update	19/09/2013	15/11/2013	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0060.
IB/0059	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	01/10/2013	n/a		
N/0058	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/08/2013	15/11/2013	PL	

N/0057	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/08/2013	15/11/2013	PL	
IAIN/0056/G	<p>This was an application for a group of variations.</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>	07/06/2013	n/a		
IAIN/0054/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a</p>	10/10/2012	n/a		

	manufacturing site for the FP - Primary packaging site				
IA/0053	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	13/08/2012	n/a		
IA/0052/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions</p> <p>B.I.c.2.b - Change in the specification parameters</p>	05/04/2012	n/a		

	and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method				
N/0051	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/12/2011	26/03/2012	PL	
IB/0050	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	07/12/2011	n/a		
N/0049	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/10/2011	n/a	PL	
IA/0048	A.1 - Administrative change - Change in the name and/or address of the MAH	30/08/2011	n/a	SmPC, Labelling and PL	
II/0047	Update of section 4.8 of the SPC to revise the information on hypertensive crisis. Further editorial changes are proposed in all languages in line with the QRD template version 7.3.1. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	23/09/2010	25/10/2010	SmPC, Annex II, Labelling and PL	The MAH has received more than one case of hypertensive crisis associated with ingestion of unknown amounts of tyramine rich foods. Therefore, the MAH proposed to update section 4.8 of the SPC in order to accurately reflect the current safety data. In detail this meant changing the wording regarding cases of hypertensive crises associated with ingestion of tyramine rich food from "one event" to "rare cases".
IB/0044	IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)	30/03/2010	n/a		

IB/0042	IB_13_b_Change in test proc. for active substance - other changes (replacement/addition) IB_12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter	03/02/2010	n/a		
IA/0046	To add a revised closure for the approved HDPE container regarding AZILECT finished product (EU/01/04/304/007). IA_36_b_Change in shape or dimensions of the container/closure - other pharm. forms	14/01/2010	n/a		
IA/0045	To add an alternative equivalent culture medium in the approved test procedure for excipient. IA_20_a_Change in test procedure for an excipient - minor change to approved test procedure	14/01/2010	n/a		
IA/0043	IA_13_a_Change in test proc. for active substance - minor change	14/01/2010	n/a		
II/0039	To update sections 4.5, 4.8 and 4.9 of the Summary of Product Characteristics (SPC) and sections 2 and 4 of the Package Leaflet (PL) to include additional post-marketing safety information following a CHMP request after the assessment of PSUR 6. In addition, the contact details of the local representative in France were updated. Update of Summary of Product Characteristics and Package Leaflet	22/10/2009	23/11/2009	SmPC and PL	Following the evaluation of the 6th PSUR the MAH was requested to update sections 4.5, 4.8 and 4.9 of the SPC and relevant sections of the PL to reflect the occurrence of cases of serotonin syndrome when Azilect is given in overdose or co-administered with antidepressants (including SNRIs), overdose cases, cases of elevated blood pressure associated with ingestion of unknown amounts of tyramine-rich foods in patients taking Azilect and a case of elevated blood pressure in a patient using a ophthalmic vasoconstrictor. In addition, the contact details of the local

					representative in France were updated.
R/0036	Renewal of the marketing authorisation.	25/06/2009	21/09/2009	SmPC, Annex II, Labelling and PL	Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Azilect continues to be favourable. With this procedure the MAH also updated the product information. This update was based on the requirements in the QRD guidelines and on the results of a readability test performed earlier by the MAH. Changes to the PI also derived from the MAH change of database for tracking of adverse events. In detail this meant that some adverse event terms were removed and that the incidence rate for some terms was updated.
IB/0041	IB_30_b_Change in supplier of packaging components - replacement/addition	07/09/2009	n/a		
IA/0040	IA_30_a_Change in supplier of packaging components - deletion of supplier	18/08/2009	n/a		
IB/0038	IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)	20/05/2009	n/a		
IB/0032	IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release	09/03/2009	n/a		
IA/0031	IA_05_Change in the name and/or address of a manufacturer of the finished product	17/02/2009	n/a	Annex II and PL	
IA/0035	IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site	13/02/2009	n/a		

IA/0034	IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms	13/02/2009	n/a		
IA/0033	IA_05_Change in the name and/or address of a manufacturer of the finished product	13/02/2009	n/a		
IB/0030	IB_10_Minor change in the manufacturing process of the active substance	22/10/2008	n/a		
IB/0029	IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS	22/10/2008	n/a		
IB/0028	IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS	22/10/2008	n/a		
IB/0027	IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS	21/10/2008	n/a		
IB/0026	IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS	21/10/2008	n/a		
IB/0023	IA_13_a_Change in test proc. for active substance - minor change IB_12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter	06/02/2008	n/a		
IB/0024	IB_37_a_Change in the specification of the finished product - tightening of specification limits	01/02/2008	n/a		
IB/0022	IB_30_b_Change in supplier of packaging components - replacement/addition	30/01/2008	n/a		

IA/0025	IA_37_a_Change in the specification of the finished product - tightening of specification limits	15/01/2008	n/a		
IA/0021	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	27/06/2007	n/a		
IA/0020	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	27/06/2007	n/a		
II/0015	<p>Following the assessment of the second PSUR, the MAH updated the product information in relation to the occurrence of hallucinations and confusional state.</p> <p>Update of Summary of Product Characteristics, Labelling and Package Leaflet</p>	22/02/2007	02/04/2007	SmPC, Annex II, Labelling and PL	The CHMP acknowledged that hallucinations and psychosis are common feature in Parkinson Disease patients and that is very difficult to single out the causal factors in a situation that is very likely multifactorial. However, the CHMP agreed that treatment with rasagiline might not be the only cause, but the likelihood of it being a contributory is high. Therefore the product information was updated to reflect the occurrence of hallucinations and psychosis in patients treated with rasagiline.
IB/0019	IB_42_a_01_Change in shelf-life of finished product - as packaged for sale	14/03/2007	n/a	SmPC	
IB/0018	IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)	14/03/2007	n/a		
IB/0016	IB_17_a_Change in re-test period of the active substance	14/03/2007	n/a		
IA/0017	IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits	20/02/2007	n/a		

IB/0009	IB_26_b_Change in the specification of immediate packaging - addition of new test parameter	02/05/2006	n/a		
IB/0008	IB_19_b_Change in specification of an excipient - addition of new test parameter	02/05/2006	n/a		
IB/0007	IB_10_Minor change in the manufacturing process of the active substance	02/05/2006	n/a		
IB/0006	IB_10_Minor change in the manufacturing process of the active substance	02/05/2006	n/a		
IA/0014	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	18/04/2006	n/a		
IA/0013	IA_05_Change in the name and/or address of a manufacturer of the finished product	06/04/2006	n/a		
IA/0012	IA_05_Change in the name and/or address of a manufacturer of the finished product	06/04/2006	n/a		
IA/0011	IA_05_Change in the name and/or address of a manufacturer of the finished product	06/04/2006	n/a		
IA/0010	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	06/04/2006	n/a		
IA/0005	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	09/08/2005	n/a		
IA/0004	IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms	15/06/2005	n/a		

II/0001	<p>The scope of the variation was to update section 4 "Possible Side Effects" of the Package Leaflet in order to have a more comprehensible wording of this section. Furthermore a statement on skin cancer and melanoma has been added.</p> <p>Update of Package Leaflet and Labelling</p>	21/04/2005	10/06/2005	Labelling and PL	Section 4.8 of the SPC lists the undesirable effects reported in the rasagiline clinical program. The section splits adverse reactions under Monotherapy and Adjunct Therapy lists. In order to have a more comprehensible approach for the patients in section 4 of the Package Leaflet "Possible Side Effects" the lists of side effects for the two indications have been combined. Information on skin cancer and melanoma as per section 4.4 of the SPC "Special warnings and special precautions for use", was also included in the PL. "In addition the list of local representatives has been updated and the labelling has been modified to be in accordance with the QRD template.
IA/0003	IA_36_b_Change in shape or dimensions of the container/closure - other pharm. forms	20/05/2005	n/a		
IA/0002	IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	25/04/2005	n/a	Annex II and PL	